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Zinc is an essential trace element that plays a vital role in maintaining many biological processes and cellular homeostasis.
Dysfunctional zinc signaling is associated with a number of chronic disease states including cancer, cardiovascular disease,
Alzheimer’s disease, and diabetes. Cellular homeostasis requires mechanisms that tightly control the uptake, storage, and
distribution of zinc. This is achieved through the coordinated actions of zinc transporters and metallothioneins. Evidence on
the role of these proteins in type 2 diabetes mellitus (T2DM) is now emerging. Zinc plays a key role in the synthesis, secretion
and action of insulin in both physiological and pathophysiological states. Moreover, recent studies highlight zinc’s dynamic role
as a “cellular second messenger” in the control of insulin signaling and glucose homeostasis. This suggests that zinc plays an
unidentified role as a novel second messenger that augments insulin activity. This previously unexplored concept would raise a
whole new area of research into the pathophysiology of insulin resistance and introduce a new class of drug target with utility for
diabetes pharmacotherapy.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a progressive and debil-
itating disorder characterized by a loss of glycaemic control
and metabolic homeostasis through the deterioration of beta
cell function [1] and relative insulin deficiency and insulin
resistance [2] in peripheral tissues including skeletal muscle,
adipose, and liver [3]. The prevalence of this metabolic
disorder is expected to increase from 171 million people in
2000 to 366 million in 2030, predominately due to changes
in nutrition, reduced physical activity, and obesity [4].
Complications arising from T2DM include renal failure [5],
blindness [6], and dyslipidemia [7], and it is widely accepted
to be a fundamental and foremost basis for cardiovascular
disease [8]. Given this projection, T2DM is becoming a
leading cause of morbidity and mortality that results in a
significant reduction in quality of life and life expectancy [9].
Recent developments in our understanding of T2DM
have been heightened by the potential relevance of dysfunc-
tional zinc signaling in this disease. Indeed, the early seminal
discovery that insulin crystals contain zinc [10] facilitated a
supportive role for this cation in diabetes. Zinc is an essential
trace element that is indispensable for its role in maintaining
normal physiological function and cellular homeostasis [11,
12]. Disturbances in zinc homeostasis have been observed in
diabetes [9, 13–18] and several other pathologies including
cancer [19, 20], autoimmune disease [21, 22], cardiovascular
disease [11, 13, 23, 24], and Alzheimer’s disease [25, 26].
Zinc has three major biological roles: catalytic, structural
and regulatory [27]. The catalytic and structural role of zinc
is well recognized, and there are many noteworthy reviews on
these functions ([28–31] and references therein). For exam-
ple, zinc is a structural constituent in numerous proteins,
including growth factors, cytokines, receptors, enzymes, and
transcription factors belonging to cellular signaling pathways
[30]. Moreover, it is implicated in numerous cellular pro-
cesses as a cofactor for an estimated 3000 human proteins
including enzymes, nuclear factors, and hormones [32].
Homeostatic mechanisms that modulate zinc absorp-
tion, distribution, cellular uptake, and excretion [27] are vital
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for maintaining cellular function. Zinc’s fundamental and
diverse role in many cellular processes requires that zinc
delivery to tissues and cells, intracellular availability, and
intracellular distribution are tightly controlled [33]. These
processes are maintained through the coordinated orchestra-
tion of a diverse family of transport proteins that modulate
the uptake, eﬄux, and compartmentalization of zinc [33].
In this context, 4 metallothioneins (MTs), 14 zinc importers
(SLC39/ZIPs), and 10 zinc exporters (SLC30/ZnTs) have
been described in mammals [34]. (Human zinc transporters
are defined as SLC30A and SLC39Awhile rodent transporters
are designated Slc30a and Slc39a. For brevity, species des-
ignations are not used in this paper and transporters will
be defined as SLC39A/ZIP and SLC30A/ZnT. Present termi-
nology and accession numbers can be obtained through the
GenBank database, http://www.ncbi.nlm.nih.gov/genbank).
The MTs are the major zinc-binding proteins in mammalian
systems that play an important regulatory role in zinc
uptake, storage, release, and distribution [35, 36]. The zinc
transporters are essential for preserving zinc homeostasis
where the ZIP transporters contribute to a net increase in
cytosolic zinc while the ZnTs cause a net decrease in cytosolic
zinc [30] (Figure 1).
In the context of T2DM, essential dietary zinc and pro-
teins that modulate zinc metabolism play a major role in
metabolic homeostasis in peripheral tissues that respond to
insulin. However, our understanding of the relationships
between zinc transport, cellular zinc signaling, and T2DM
is limited. Accordingly, this paper aims to delineate the role
of zinc transporter systems, their mechanisms of action, and
possible roles in disease with a particular focus on T2DM.
2. Zinc and Zinc Transporters: Regulation,
Signaling, and Cellular Mechanisms
There is approximately 2–4 g of zinc in the human body but
the concentration of the mobile pool of zinc ions in plasma
is only 12–16 μM [9]. Given the low plasma concentration of
zinc and its importance in cellular processes, it is essential
that the availability and distribution of “free zinc” (“free
zinc” is an operative term that is used to diﬀerentiate the
zinc that is implicated in signaling transduction from that
of zinc tightly bound to protein and thermodynamically
unavailable) is tightly controlled [37]. Diet replenishes
approximately 1% of the total body zinc lost by intestinal
excretion in humans which is principally achieved by intesti-
nal absorption [33]. Zinc delivery to tissues and cells and its
intracellular distribution is also tightly regulated by a family
of proteins that control uptake, eﬄux, and compartmental-
ization of zinc. In mammals, this is accomplished by an array
of zinc transporters encoded by at least 27 genes from 3
families. These are the SLC30 (CDF/ZnT: vertebrate cation
diﬀusion facilitator family proteins), SLC39 (ZIP: Zrt-,Irt-
like Proteins) solute transporters, and the zinc-sensitizing
MTs [18, 20, 34, 38–40] (Figure 1). The MTs play an impor-
tant regulatory role in zinc uptake, storage, distribution, and
release [29, 36]. The ZIP family members facilitate the influx
of zinc into the cytosol from the outside of the cells and from
the lumen of intracellular compartments, while the ZnT fam-
ily members enable the transport of zinc out of the cytosol
into the lumen of intracellular organelles or to the outside of
the cell [27, 34, 40, 41]. Both ZIP and ZnT transporters work
in an opposite but coordinated way to maintain cellular zinc
homeostasis. Although the tissue distribution of the ZIP and
ZnT family has been investigated in detail [42] (Table 1), in
addition to diﬀerential expression based on gender [43], their
mechanisms of action are still not well understood.
2.1. The SLC39/ZIP Family. ZIP transporters were first iden-
tified as “Zrt-, Irt-like Proteins” following their identifica-
tion in yeast Saccharomyces cerevisiae (Zrt; zinc regulated
transporter) and their similarity to the Fe(II) transporter
Irt1 protein from the plant Arabidopsis thaliana [44, 45]. In
these studies, Zhao and Eide [44] showed that overexpression
of Zrt1 in yeast cells increased high aﬃnity uptake of 65Zn
and that this was reduced in Zrt1 mutant cells resulting in
poor growth in zinc-limited media. Since their discovery,
the ZIP family of proteins has grown to more than 100
members including those from insects, bacteria, nematodes
and mammals [38, 46]. In mammals, members of this family
are designated SLC39 for solute carrier [40]. Most ZIP
transporters are predicted to have eight transmembrane
(TMD) domains and similar predicted topologies (Figure 1).
Characteristics of this topology have been confirmed for
yeast [47]. Many of the family members have a long loop
region between TMD III and IV that frequently contains a
histidine-rich region [(HXn, n = 3 to 5)] [40] that is sug-
gested to be a putative zinc-binding domain [48]. The
majority of ZIP proteins share a similar predicted topology
where both the N and C-termini are extracytoplasmic [40]. A
key feature of ZIP transporters is that they facilitate the influx
of zinc into the cytosol from the extracellular space and from
the lumen of intracellular compartments into the cytoplasm
[30].
2.2. SLC30/ZnT Family. The first ZnT protein (termed
ZnT1) was described by Palmiter and Findley [49]. ZnT1 was
isolated from a rat kidney cDNA library and shown to restore
zinc resistance when transfected into a zinc sensitive baby
kidney hamster (BHK) cell line under high levels of extracel-
lular zinc [49]. To date, the mammalian SLC30 family code
for ten zinc transporters (ZnTs), ZnT1-10 [50]. The ZnT
family of zinc transporters enables the transport of zinc out
of the cytosol into the lumen of intracellular organelles or to
the outside of the cell [27, 34, 40, 41, 51] (Figure 1). Most
members of this family have six predicted transmembrane
domains (TMDs) and are predicted to have cytoplasmic
amino and carboxy termini (Figure 1). In addition, ZnTs
characteristically harbour a long histidine-rich loop between
TMD IV and V [(HXn, n = 3 to 6)] and, similar to the ZIPs,
place this potential zinc-binding site in the cytosol [52]. An
exception to this rule is the human ZnT5 transporter which is
predicted to contain 15 TMDs [53] and ZnT6 which har-
bours a serine-rich loop between TMDs IV and V [54]. Most
ZnTs form homodimers with the exception of ZnT5 and
ZnT6 which interact to form heterodimers to transport
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Figure 1: Subcellular localization and direction of transport of the zinc transporter families, ZnT and ZIP. Arrows show the direction of zinc
mobilization for the ZnT (green) and ZIP (red) proteins. A net gain in cytosolic zinc is achieved by the transportation of zinc from the
extracellular region and organelles such as the endoplasmic reticulum (ER) and Golgi apparatus by the ZIP transporters. Cytosolic zinc is
mobilized into early secretory compartments such as the ER and Golgi apparatus by the ZnT transporters. Figures were produced using
Servier Medical Art, http://www.servier.com/.
zinc into the early secretory pathway [55]. ZnT proteins
have been identified in intracellular compartments that are
usually associated with endosomes, Golgi apparatus, or the
endoplasmic reticulum (Table 1) [56]. The tissue-specific
expression of the ZnTs is varied with the exception of ZnT8
which is expressed predominately in insulin-producing beta
cells of the pancreas [57, 58].
3. Modes of Zinc Signaling, Zinc Transporters,
and Insulin Signaling
Zinc transporters typically act as zinc sensors, responding to
zinc availability to maintain intracellular zinc homeostasis.
The mode in which cellular homeostasis is achieved through
zinc and zinc transporters is complex and comprehensive,
and there are many significant reviews on these processes
[3, 26, 30, 33, 34, 38–40, 50, 56, 104]. Accordingly, the fol-
lowing section aims to briefly introduce a number of impor-
tant concepts by which zinc and zinc transporters main-
tain cellular homeostasis and to highlight, where possible,
the links between zinc transporter modulation and insulin
signaling pathways.
3.1. Modes of Zinc Signaling. Given the large array of zinc
transporters that are dedicated to controlling zinc homeosta-
sis (Table 1), it is not surprising that this cation is quickly tak-
ing precedence as a leading signaling molecule analogous to
calcium. In this context two modes of zinc signaling have
been described: “early zinc signaling” (EZS) and “late zinc
signaling” (LZS) [105, 106] (Figure 2). EZS involves a rapid
change in intracellular levels of free zinc that occurs in
minutes due to an extracellular stimulus that is transcription
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Table 1: Zinc transporters, cellular location, tissue-specific expression, and disease associations.
Zinc transporter Cellular localization Tissue expression Disease associations References
SLC39A1/ZIP1 Plasma membrane Ubiquitously expressed Prostate cancer [59–61]
SLC39A2/ZIP2 Plasma membrane Blood, prostate Carotid artery disease [62–64]
SLC39A3/ZIP3
Plasma membrane, intracellular
compartments
Mammary gland, prostate Unknown [60, 65]
SLC39A4/ZIP4 Apical membranes
Small intestine, stomach, colon,
kidney, brain
Pancreatic cancer, acrodermatitis
enteropathica (AE)
[62, 66, 67]
SLC39A5/ZIP5 Basolateral membranes
Pancreas, kidney, liver, spleen,
colon, stomach
Unknown [68, 69]
SLC39A6/ZIP6 Plasma membrane Ubiquitously expressed Breast cancer [70]
SLC39A7/ZIP7
Golgi apparatus, endoplasmic
reticulum
Ubiquitously expressed Breast cancer [71, 72]
SLC39A8/ZIP8 Vesicles Ubiquitously expressed Unknown [73, 74]
SLC39A9/ZIP9 Trans-Golgi network Ubiquitously expressed Unknown [75]
SLC39A10/ZIP10 Plasma membrane Ubiquitously expressed Breast cancer [76, 77]
SLC39A11/ZIP11 Unknown Mammary gland Unknown [78]
SLC39A12/ZIP12 Unknown Retina, brain, testis, lung Schizophrenia [79]
SLC39A13/ZIP13 Golgi apparatus Ubiquitously expressed Ehlers-Danlos syndrome [80, 81]
SLC39A14/Zip14 Plasma membrane Ubiquitously expressed Asthma [82, 83]
SLC30A1/ZnT1 Plasma membrane Ubiquitously expressed
Alzheimer’s disease, Pancreatic
cancer
[19, 25, 49]
SLC30A2/ZnT2 Vesicles, lysosomes
Pancreas, kidney, testis, epithelial
cells, small intestine
Unknown [84]
SLC30A3/ZnT3 Synaptic vesicles Brain, testis Alzheimer’s disease [85, 86]
SLC30A4/ZnT4 Intracellular compartments
Mammary gland, brain, small
intestine, placenta, blood,
epithelial cells
Alzheimer’s disease [25, 87]
SLC30A5/ZnT5 Secretory vesicles, Golgi apparatus Ubiquitously expressed Osteopenia [53, 88]
SLC30A6/ZnT6 Secretory vesicles, Golgi apparatus
Small intestine, liver, brain,
adipose tissue
Alzheimer’s disease [25, 54]
SLC30A7/ZnT7 Golgi apparatus
Retina, small intestine, liver,
blood, epithelial cells, spleen
Prostate cancer [89, 90]
SLC30A8/ZnT8 Secretory vesicles Pancreatic B-cells Type 1 and 2 diabetes mellitus [57, 91, 92]
SLC30A9/ZnT9 Cytoplasm, nucleus Ubiquitously expressed Unknown [93]
SLC30A10/ZnT10 Unknown Liver, brain
Parkinson’s disease, dystonia,
liver disease
[94–96]
MT1 Cytoplasm, nucleus, mitochondria Ubiquitously expressed Unknown [97, 98]
MT2 Cytoplasm, nucleus, mitochondria Ubiquitously expressed Unknown [99, 100]
MT3 Cytoplasm, nucleus Brain, testis Alzheimer’s disease [101]
MT4 Cytoplasm, nucleus Squamous epithelia Unknown [102, 103]
independent [30]. This was revealed in studies by Yamasaki
et al. [105] who reported in mast cells a rapid increase in
intracellular free zinc from the perinuclear region that
includes the endoplasmic reticulum (ER) withinminutes fol-
lowing extracellular stimulus with the high aﬃnity IgE recep-
tor (FcεRI). These authors described this phenomenon as a
“zinc wave” that is dependent on both calcium influx and
MEK signaling, although calcium influx alone was not
suﬃcient to induce the zinc wave while MEK activation
was essential. LZS is also triggered by an extracellular signal
and involves transcriptional-dependent changes in expres-
sion of proteins implicated in zinc homeostasis such as
storage proteins or transporters [30, 106]. Both EZS and LZS
modulate numerous cellular processes involved in cell diﬀer-
entiation, proliferation, and growth [35]. The importance of
zinc for cell growth and proliferation is well recognized, and
deficiencies in zinc cause growth retardation in all organisms
investigated [35].
In 1980, Coulston and Dandona [107] discovered that
zinc exerted a potent stimulatory eﬀect upon lipogenesis in
rat adipocytes independent of and additive to that of insulin.
These findings suggested that the eﬀects of this cation may
have physiological relevance in controlling insulin signaling
pathways since zinc is essential for the crystallization of
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Figure 2: Early zinc signaling (EZS) and late zinc signaling (LZS). EZS involves transcription-independent mechanisms where an extracellular
stimulus directly induces an increase in zinc levels within several minutes by releasing zinc from intracellular stores (e.g., endoplasmic
reticulum). LSZ is induced several hours after an external stimulus and is dependent on transcriptional changes in zinc transporter
expression. Components of this figure were produced using Servier Medical Art, http://www.servier.com/ and adapted from Fukada et al.
[30].
insulin in hexameric complexes [10, 41] and is cosecreted
with insulin on exposure to high glucose [41]. Similarly,
May and Contoreggi [108], utilizing supraphysiological con-
centrations (250–1000 μM) of ZnCl2, revealed a role for
this cation in stimulating glucose transport and oxidation,
incorporation of glucose carbon into glyceride-glycerol and
glyceride-fatty acid, and inhibition of ritodrine-stimulated
lipolysis in rat adipocytes. Equally, Ezaki [109] showed that
rat adipocyte cells treated with ZnSO4 for 30 minutes stim-
ulated cAMP phosphodiesterase and glucose transporter
translocation from the intracellular region to the plasma
membrane. Moreover, these authors proposed that this
process was not dependent on insulin receptor stimulated
kinase activity. This was in contrast to studies by Tang and
Shay [110] who demonstrated that treatment of 3T3-L1
adipocytes over 5–10 minutes with ZnCl2 increased tyrosine
phosphorylation of the IR-β subunit of the insulin receptor
and enhanced the transport of glucose in the absence of
insulin through the PI-3-kinase signal transduction pathway.
These studies have since been further delineated with
investigations into the role of zinc as an inhibitor of protein
tyrosine phosphatases [51, 105, 111]. In fact, inhibition of
protein tyrosine phosphatase 1B (PTP1B, a negative regu-
lator of insulin signaling) activity ameliorates high-fat-diet-
induced insulin resistance and lipid disorders in mice [112].
Furthermore, mice with a genetic ablation of PTP1B or
pharmacological inhibition of its expression and activity are
lean and have increased insulin sensitivity [113] and can
restore insulin sensitivity in the liver of insulin receptor
substrate 2-deficient mice [114].
Several groups have examined the mechanisms of the
insulin-mimetic activity of zinc on glucose [108, 110, 115–
119] and lipid [107, 119] metabolism. Cumulative evidence
has revealed zinc as a direct signaling molecule implicated
in extracellular signal recognition [105], second messenger
metabolism [120], protein kinase activity [110], protein
phosphorylation [119, 121], and the modulation of tran-
scription factors [122] and highlights zinc’s dynamic role
as a “cellular second messenger” in the control of insulin
signaling and glucose homeostasis [33, 105, 123]. Insulin is
a critically important anabolic hormone implicated in main-
taining normal physiological blood glucose. Zinc mediates
these eﬀects in part through the inhibition of protein tyrosine
phosphatases which increase the net phosphorylation of
the insulin receptor and activate its signaling cascade [51,
111]. Accordingly, the eﬀects of zinc on cellular homeostasis
appear to be numerous and include the stimulation of
glucose uptake and lipogenesis in adipocytes [110], tyrosine
phosphorylation of the insulin/IGF-1 receptor and insulin
receptor substrate-1 [51, 111, 121], activation of epidermal
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growth factor receptor [72, 121], inhibition of protein tyro-
sine phosphatase (PTP) [33, 111], and subsequent activation
of mitogen-activated protein kinases (MAPKs) including
extracellular-signal-regulated kinases 1 and 2 (ERK1/2), c-
Jun N-terminal kinase (JNK) and p38 [20], and an increase
in glycogen synthesis through the inhibition of glycogen
synthase kinase-3 [115].
Several potential mechanisms have been suggested for the
role of zinc aﬀecting insulin action including the modulation
of insulin receptor tyrosine kinase activity and subsequent
defects in insulin-stimulated muscle glycogen synthesis [124,
125]. This raises the prospect that zinc plays a previously
unidentified role as a novel second messenger that augments
insulin activity. This concept raises a whole new area of
research into the pathophysiology of insulin resistance and
introduces a new class of drug target with utility for diabetes
pharmacotherapy. However, the mechanistic details of how
insulin aﬀects intracellular zinc transport and the subsequent
signaling cascades associated with glucose homeostasis and
insulin resistance are yet to be defined.
3.2. Zinc and Zinc Transporters. The expression and cellular
distribution of ZIPS and ZnTs are predominately (but not
always) regulated by changes in extracellular and intracellu-
lar zinc concentrations [50]. The first study to delineate a role
for zinc transporters and zinc homeostasis was performed in
1995 when Palmiter and Findley [49] isolated ZnT1 from a
rat kidney cDNA expression library. These authors revealed
that transfection of rat ZnT1 cDNA conferred resistance to
high levels of extracellular zinc in the zinc-sensitive baby
hamster kidney (BHK) cell line. Moreover, ZnT1 overexpres-
sion in the BHK cells increased 65Zn eﬄux and reduced the
intracellular steady-state concentration of zinc. Following
these studies, in 1996 the second ZnT was isolated (ZnT2)
(Palmiter et al. [84]). Similar to ZnT1, overexpression of rat
ZnT2 cDNA conferred zinc resistance to BHK cells. However,
unlike ZnT1 which is located in the plasma membrane and
lowers cellular zinc by stimulating cellular zinc eﬄux, ZnT2
is localized on vesicles and accumulates high concentrations
of zinc in the endosomal/lysosomal compartment. ZnT2 is
also associated with the inner mitochondrial membrane in
mouse MEC mammary cells [126], and attenuation of ZnT2
mRNA expression reduced mitochondrial zinc uptake and
mitochondrial zinc pools.
In studies on rats fed a diet low in zinc (<1mg Zn/Kg),
low expression of ZnT2 was observed in the kidney and small
intestine in comparison to rats fed an adequate intake of
dietary zinc (30mg Zn/Kg) [127]. Likewise, ZnT1 and ZnT2
were markedly increased in these tissues when supplied with
greater concentrations of dietary zinc (180mg Zn/Kg) while
ZnT4 was refractory to changes in zinc uptake. These find-
ings suggested that a metal-responsive mode of regulation
for at least ZnT1 and ZnT2 will involve metal-responsive
elements (MREs) in the promoters of these genes. Indeed, the
induction of the MTs by metals is mediated by several MREs
located in the promoter region of MT genes that recruits the
metal response-element transcriptional factor (MTF-1) and
is responsible for its transcriptional regulation [128]. Studies
in mouse embryo fibroblasts with homozygous deletions of
the MTF-1 gene revealed that this protein was essential for
basal and zinc-responsive regulation of ZnT1 [129]. MREs
have been identified in the ZnT1 promoter [49], and ZnT5
has multiple metal-responsive elements (MREs) in its pro-
moter region that mediate zinc-induced transcriptional acti-
vation [40, 130].
Many ZnT and ZIP transporters are also regulated by
hormones or cytokines (see Lichten and Cousins [38] for a
comprehensive review). In LNCaP and PC-3 prostate cancer
cells, ZIP1 is regulated by testosterone and prolactin and is
consistent with the rapid cellular accumulation and uptake of
zinc in these cells [131]. ZIP6 and ZIP14 mRNA expression
respond to estrogen stimulation and have reduced response
to tamoxifen or fulvestrant [132]. ZIP8 is strongly induced
by TNF-α in primary human lung epithelial cells [133, 134]
and A459 lung cancer cells [134] concomitant with an
increase in intracellular zinc. Recent evidence suggests that
the mechanism of TNF-α induction of ZIP8 is through the
NF-κB pathway [134]. ZIP14 is upregulated by IL-6 (but not
by TNF-α) in mouse hepatocytes where it is suggested to
play a role in hypozincemia that accompanies the acute phase
response to inflammation and infection [135].
Some transporters alter their transcriptional and post-
transcriptional expression in response to zinc fluctuations,
while others alter their subcellular localization [33]. For
example, ZnT1 is predominately localized to the plasma
membrane but has recently been shown to locate to the endo-
plasmic reticulum complexed with EVER transmembrane
channel-like proteins in human keratinocytes [136]. EVER
and ZnT1 complexes influence intracellular zinc concentra-
tion and downregulate transcription factors stimulated by
zinc (MTF-1) or cytokines (c-Jun and Elk). Similarly, Kim
et al. [137] revealed that the transfection of human embry-
onic kidney (HEK293) cells with mZIP4 resulted in the
localization of this transporter to cytoplasmic vesicles in
the perinuclear region. Subsequent depletion of zinc from
the HEK293 cells following treatment with the heavy metal
chelator TPEN resulted in a redistribution of mZIP4 towards
the plasma membrane. Equally, mZIP1 and mZIP3 were
found to transit between the plasma membrane and intra-
cellular compartments in zinc-depleted HEK293 cells [60].
ZnT5 is located in the Golgi apparatus and facilitates
the transport of zinc into the Golgi lumen for storage.
Overexpression of ZnT5 in HeLa cells facilitates zinc uptake
into intracellular vesicles suggesting that ZnT5 is capable of
accumulating zinc in intracellular compartments [38].
Importantly, ZnT5 is thought to be responsible for loading
zinc to secretory, membrane-bound, or organelle-resident
proteins to facilitate biological activity of proteins [138]. An
important component of ZnT5 as a Golgi zinc influx trans-
porter is its critical role in counteracting the eﬀects of Zip7 to
maintain the balance of zinc mobilization between the Golgi
and cytosol.
ZnT4 and ZnT6 have been shown to traﬃc from the
trans-Golgi network to the cytoplasmic vesicular compart-
ment with increasing concentrations of extracellular zinc
in rat kidney cells [54]. In transient transfection experiments,
Milon et al. [139] revealed that human ZIP1 (hZIP1) has
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vesicular localization in COS-7 cells. In contrast, transfec-
tion of hZIP1 into K562 cells showed plasma membrane
localization and suggests that the localization for this protein
is under the influence of zinc-responsive regulation. In
HEK293 kidney cells grown in zinc-replete medium, mouse
ZIP1 and ZIP3 (mZIP) were localized to intracellular
organelles [60]; however in the absence of zinc, these pro-
teins were preferentially localized to the plasma membrane
suggesting that they are modulated at the posttranslational
level to control zinc homeostasis [60].
Although many zinc transporters respond to fluctuating
zinc levels and alter their subcellular localization, ZIP7 is an
exception and is restricted constitutively to the membrane of
the Golgi apparatus and endoplasmic reticulum [34]. Studies
in human cells including lung fibroblasts (WI-38), prostate
epithelial cells (RWPE1), erythroleukemia cells (K-562), and
mammary gland epithelial cells (MCF-7) showed ZIP7 anti-
body fluorescence staining in the perinuclear region of the
Golgi apparatus [71]. This was confirmed by treating MCF
cells with brefeldin A, a fungal macrocyclic known to disrupt
the Golgi apparatus, prior to immunofluorescent staining
[71]. Furthermore, ZIP7 gene expression and intracellular
location are not altered in response to changes in intracellular
zinc status [71]. In this context, it is unlikely that ZIP7 is
upregulated by cytosolic zinc concentrations. In contrast,
ZIP7 has been shown to be regulated at the post-translational
level by suppression of ZIP7 protein translation in response
to high zinc concentrations [38, 71]. ZIP7 is involved in the
release of zinc from intracellular stores and activation ofmul-
tiple tyrosine kinases through zinc-mediated inactivation of
protein phosphatases [20]. The presence of multiple MAPK-
binding motifs and phosphorylation sites on the cytoplasmic
domain of ZIP7 suggests that zinc transport by this protein
is regulated by phosphorylation [20]. In a recent study,
the phosphorylation of the endoplasmic reticulum ZIP7 by
protein kinase CK2 was associated with the gated release of
zinc from intracellular stores leading to activation of tyrosine
kinases and the phosphorylation of AKT and extracellular
signaling kinases 1 and 2 [140]. This raises an interesting
mechanism for the regulation of ZIP7 through the activity of
CK2 possibly through insulin-mediated signaling pathways.
Interestingly, treatment of pancreatic beta cells with 100 nM
insulin over 4 hours resulted in a significant increase in CK2
kinase activity [141]; however the complete physiological
importance of this eﬀect is still to be elucidated.
It has been suggested that increased expression of ZIP7
could prolong growth factor signaling and contribute to
dysfunctional regulatory mechanisms in a number of disease
states characterized by the increased activation of tyrosine
kinases [20]. Equally decreased expression of ZIP7 might
contribute to a deactivation of signaling events associ-
ated with cellular signaling through constitutively activated
protein phosphatases. Although there are several studies
implicating increased protein-tyrosine phosphatase activity
as contributing to insulin resistance [51, 110, 111, 113, 114,
121, 142–145], the evidence linking insulin signaling to zinc
transport mechanisms and zinc-mediated signaling events is
lacking.
3.3. Zinc Transporters and Zinc Signaling in T2DM. The
interaction between zinc homeostasis and T2DM has been
examined based on the insulinomimetic eﬀect of zinc on
insulin signaling. Our recent understanding of T2DM and
the role that zinc signaling plays in maintaining cellular
homeostasis has prompted intensive research eﬀorts into
dysregulated cellular zinc partitioning in this chronic disease.
Given that health issues associated with T2DM have global
significance, there is considerable interest in elucidating the
molecular mechanisms responsible for insulin resistance and
defects in glycaemic control. Zinc has an integral role in
the processing, storage, secretion, and action of insulin in
response to changes in elevated glucose concentrations [33,
118]. In vivo, dietary zinc supplements given to db/db mice
attenuated hyperglycemia and hyperinsulinemia and ele-
vated pancreatic zinc concentrations [117]. Moreover, zinc
treatment significantly improved glucose clearance in genet-
ically nonobese IDE-deficient diabetic rats and mice with
concomitant diabetes and obesity [123, 146]. In fact, zinc-
deficient animals are less sensitive to insulin [147], and oral
administration of zinc in animals and humans improves
glycaemic control in type 1 and type 2 diabetic patients [3].
In humans, Jansen et al. [9] found a significant reduction
in plasma zinc levels in type 1 diabetes and T2DM patients
compared to healthy controls and suggest that oral supple-
mentation of zinc may qualify as a potential adjunct therapy
in T2DM patients by promoting insulin signaling. A recent
systemic review of the literature and meta-analysis on 25
studies reporting the eﬀects of zinc supplementation on
T2DM revealed that those patients receiving the zinc therapy
had improved glycaemic control and health lipid parameters
[148].
In the context of zinc transporter systems the most well
studied in diabetes is ZnT8. In human type 1 diabetes, ZnT8
was targeted by autoantibodies in 60%–80% of new onset
cases [149]. Recently ZnT8 is purported to have a role in
T2DM. The expression of ZnT8 is predominately within the
insulin-producing beta cells of the pancreas [57] but has also
been identified at much lower levels in other tissues such
as kidney and testis [42]. ZnT8 overexpression in INS-1
cells enhanced glucose-stimulated insulin secretion [57] and
the downregulation of ZnT8 in this system showed reduced
insulin content and secretion in response to a hyperglycaemic
stimulus [150]. Mice with a targeted beta cell ZnT8 “knock
out” display deficiencies in glucose intolerance [151]. More-
over, ZnT8 null mice display diet-dependent abnormalities
in glucose tolerance [152], insulin secretion [152, 153], and
body weight [152, 154].
Several genomewide association studies (GWASs) have
implicated ZnT8 in T2DM in humans [8, 155–157]. Thus,
having two copies of the at-risk polymorphic variant
rs13266634, a nonsynonymous single nucleotide polymor-
phism (SNP) (Arg325Trp) in ZnT8 is associated with a 43%
increase risk of developing diabetes [158]. Recently a GWAS
study identified variants in ZnT8 to be associated with
a greater risk for T2DM from 1508 Chinese Han T2DM
patients and 1500 age- and gender-matched healthy controls
[156]. All subjects were genotyped for 3 tagging SNPs
(rs2466295, rs4876703, rs11558471). The genotype and the
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allele distributions of the AA genotype of rs11558471 were
more common in the T2DM subjects than the control
group [156]. The frequency of the A-C-A haplotype was
significantly greater in the T2DM subjects compared to
the controls while the A-G-A haplotype was significantly
reduced in the T2DM subjects compared to the controls.
These authors predict that the A-C-A haplotype is a risk
factor for T2DM while the A-G-A haplotype is protective for
T2DM in Chinese Han people [156]. Accordingly, it is
suggested that polymorphisms in ZnT8 aﬀect insulin secre-
tion and increase the risk for T2DM as binding of zinc is
paramount for the crystallization of insulin [151, 152].
Several other zinc transporters, although not directly
associated with diabetes, are implicated in insulin-mediated
signaling and glycaemic control in animal models and
humans. Huang et al. [159] demonstrated that overex-
pression of ZnT7 in pancreatic insulinoma RIN5mf cells
increased insulin secretion upon glucose stimulation. Fol-
lowing these studies Huang et al. [160] revealed that ZnT7
knockout mice were more susceptible to diet-induced glu-
cose intolerance and insulin resistance, and this was con-
comitant with a reduction in the mRNA expression of the
insulin receptor, insulin receptor substrate 2, and Akt1 in
primary skeletal myotubes. ZnT3, ZnT5, and ZnT8 gene
expression is diﬀerentially regulated by glucose in INS-1E
cells and ZnT3 knockdown decreased insulin gene expression
and secretion and resulted in hyperglycemia in strepto-
zotocin-treated ZnT3 null mice [161]. Similarly, elevated
glucose concentrations increased free cytosolic zinc in mouse
pancreatic islets and were associated with an increase in the
mRNA expression of ZIP6-8 [162]. These authors suggested
that glucose induces cytosolic zinc leading to the processing
and storage of insulin and associated increase in the ZIP
importers.
The studies presented on the role of zinc and zinc trans-
porters in cell-based and rodent knockout and/or overex-
pression systems and allelic variants in humans suggest that
this family of proteins plays a key role in the pathogenesis
of diabetes. Identifying how zinc and zinc transporters play
a role in insulin signaling and glycaemic control will be of
upmost importance in elucidating novel therapeutic options
for the treatment and prevention of T2DM.
4. Conclusions and Perspectives
Zinc is an essential trace metal that is implicated in many
physiological and metabolic processes. The ubiquitous
nature of zinc in physiological systems suggests that atypical
levels are likely to have many biological and clinical eﬀects.
The true significance of zinc in cellular signaling is just
emerging. In this context the zinc transporters play an
essential role in insulin and glucose homeostasis. The inhi-
bition of protein tyrosine phosphatases by zinc under
physiological conditions involving zinc transporter mecha-
nisms has widespread implications for understanding insulin
resistance and disease progression. While a clear role for
ZnT8 in insulin production and susceptibility to T2DM
has been established, in the future, confirmation of a role
for zinc transporters and zinc signaling in insulin activity
will establish zinc homeostasis as a key element in the
pathogenesis of T2DM.
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